Cardiff Oncology, Inc.(CRDF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CRDF Cardiff Oncology, Inc.

Closed 09-09 16:00:00 EDT

1.05

-0.05

-4.55%

盘后1.10

+0.05+4.76%

19:30 EDT

High1.08	Low1.02	Vol715.99K
Open1.08	D1 Closing1.10	Amplitude5.45%
Mkt Cap81.56M	Tradable Cap79.00M	Total Shares77.67M
T/O753.25K	T/O Rate0.95%	Tradable Shares75.24M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CRDF","market":"US","secType":"STK","nameCN":"Cardiff Oncology, Inc.","latestPrice":1.05,"timestamp":1788984000000,"preClose":1.1,"halted":0,"volume":715985,"hourTrading":{"tag":"盘后","latestPrice":1.1,"preClose":1.05,"latestTime":"19:30 EDT","volume":15968,"amount":16977.5341,"timestamp":1788996609905,"change":0.05,"changeRate":0.047619,"amplitude":0.047619},"delay":0,"changeRate":-0.04545454545454549,"floatShares":75235000,"shares":77673000,"eps":-0.591396,"marketStatus":"Closed","change":-0.05,"latestTime":"09-09 16:00:00 EDT","open":1.08,"high":1.08,"low":1.02,"amount":753250.2292875,"amplitude":0.054545,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.591396,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789027200000},"marketStatusCode":5,"adr":0,"listingDate":1059624000000,"exchange":"NASDAQ","adjPreClose":1.1,"preHourTrading":{"tag":"盘前","latestPrice":1.09,"preClose":1.1,"latestTime":"09:29 EDT","volume":3647,"amount":3826.6698196999996,"timestamp":1788960570120,"change":-0.01,"changeRate":-0.009091,"amplitude":0.090909},"postHourTrading":{"tag":"盘后","latestPrice":1.1,"preClose":1.05,"latestTime":"19:30 EDT","volume":15968,"amount":16977.5341,"timestamp":1788996609905,"change":0.05,"changeRate":0.047619,"amplitude":0.047619},"volumeRatio":1.168982,"impliedVol":2.0092,"impliedVolPercentile":0.7809},"requestUrl":"/m/hq/s/CRDF/wiki","defaultTab":"wiki","newsList":[{"id":"2664181510","title":"Cardiff Oncology to Present at RAS-Targeted Drug Development Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2664181510","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664181510?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:02","pubTimestamp":1788346949,"startTime":"0","endTime":"0","summary":"Cardiff Oncology to present at RAS-targeted drug development summitCardiff Oncology will present at the 8th Annual RAS-Targeted Drug Development Summit on Sept. 8 at 9:00 a.m. ET.Mani Mohindru will jo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL8bcNWY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","IE00BN0W2W23.USD","IE00BKPKM429.USD","LU2210149790.SGD","BK4588","LU2095319765.USD","BK4112","SG9999014021.USD","SG9999014013.SGD","LU2210150020.SGD","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BQXX3C00.GBP","CRDF","IE00B64PRP62.GBP","IE00BQXX3F31.USD","SG9999014005.SGD","SG9999014039.USD","BCDF","NDAQ","BK4139","BK4585","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","IE00BQXX3D17.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662741472","title":"Cardiff Oncology Announces Special Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2662741472","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662741472?lang=en_us&edition=fundamental","pubTime":"2026-08-27 04:01","pubTimestamp":1787774507,"startTime":"0","endTime":"0","summary":"Cardiff Oncology announces special shareholder meetingCardiff Oncology will hold a special stockholder meeting in San Diego on Oct. 22, 2026.Votes will be sought to raise authorized capital stock to 3","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL831C9B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659126232","title":"Cardiff Oncology Announces Special Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2659126232","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659126232?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:03","pubTimestamp":1786737807,"startTime":"0","endTime":"0","summary":"Cardiff Oncology announces special shareholder meetingCardiff Oncology plans a special stockholder meeting in San Diego in October 2026.Vote on amending the certificate of incorporation to raise autho","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL1K41xB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659149626","title":"Replimune Q1 Net Loss Narrows as Expenses Decline","url":"https://stock-news.laohu8.com/highlight/detail?id=2659149626","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659149626?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:14","pubTimestamp":1786709664,"startTime":"0","endTime":"0","summary":"Replimune Q1 net loss narrows as expenses declineOverviewUS oncolytic immunotherapy firm's fiscal Q1 net loss narrowed year-over-yearCompany received FDA accelerated approval for TUDRIQEV in advanced ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL1N44B0EB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNM","REPL","BK4563","BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659416241","title":"Elicio Therapeutics Q2 Net Loss Narrows as R&D Expenses Fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2659416241","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659416241?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:09","pubTimestamp":1786651788,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics Q2 net loss narrows as R&D expenses fallOverviewUS biotech firm's Q2 net loss narrowed yr/yr as R&D expenses declinedCompany completed $15 mln financing in July, extending cash run","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A13X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELTX","CRDF","IMNM","BK4139","ARTL","BK4563","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659508152","title":"PDS Biotechnology Q2 Net Loss Widens Slightly as Operating Costs Fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2659508152","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659508152?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:39","pubTimestamp":1786624789,"startTime":"0","endTime":"0","summary":"PDS Biotechnology Q2 net loss widens slightly as operating costs fallOverviewUS cancer immunotherapy developer's Q2 net loss widened slightly yr/yrOperating expenses fell due to lower clinical trial a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A0LJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","BK4139","PDSB","BK4563","IMNM","CRDF","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659156740","title":"Pyxis Oncology Q2 Loss Widens on Increased Administrative Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2659156740","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659156740?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:16","pubTimestamp":1786619767,"startTime":"0","endTime":"0","summary":"Pyxis Oncology Q2 loss widens on increased administrative costsOverviewUS cancer therapeutics developer's Q2 net loss widened yr/yr as operating expenses roseCompany completed $50 mln private placemen","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A0GD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNM","BK4139","BK4563","PYXS","APRE","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658908974","title":"William Blair Downgrades Cardiff Oncology to Market Perform From Outperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2658908974","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658908974?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:34","pubTimestamp":1786534498,"startTime":"0","endTime":"0","summary":"Cardiff Oncology (CRDF) has an average rating of overweight and mean price target of $6.21, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ma","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658397158","title":"Cardiff Oncology, Inc. : William Blair Cuts to Market Perform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2658397158","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658397158?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:02","pubTimestamp":1786532562,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4490TD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658416509","title":"Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Cardiff Oncology (CRDF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658416509","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658416509?lang=en_us&edition=fundamental","pubTime":"2026-08-12 07:20","pubTimestamp":1786490407,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Neurogene (NGNE) and Cardiff Oncology (CRDF). Neur...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-neurogene-ngne-and-cardiff-oncology-crdf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-neurogene-ngne-and-cardiff-oncology-crdf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","XLV","LU0128526141.USD","HCSG","XBI","LABU","BK4139","CRDF","BK4581","LU0029874061.USD","BK4585","NGNE","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658949767","title":"William Blair downgrades Cardiff Oncology (CRDF) to a Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2658949767","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658949767?lang=en_us&edition=fundamental","pubTime":"2026-08-12 06:25","pubTimestamp":1786487121,"startTime":"0","endTime":"0","summary":"Cardiff Oncology received a Hold rating and price target from William Blair analyst Andy Hsieh today. Hsieh covers the Healthcare sector, focusing ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/william-blair-downgrades-cardiff-oncology-crdf-to-a-hold-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/william-blair-downgrades-cardiff-oncology-crdf-to-a-hold-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658945301","title":"Cardiff Oncology Q2 EPS $(0.14) Beats $(0.16) Estimate, Sales $104.000K Beat $70.714K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2658945301","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658945301?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:40","pubTimestamp":1786480830,"startTime":"0","endTime":"0","summary":"Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent. This is a 33.33 percent increase over losses of $(0.21) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61128402/cardiff-oncology-q2-eps-0-14-beats-0-16-estimate-sales-104-000k-beat-70-714k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Cardiff Oncology Q2 EPS $(0.14) Beats $(0.16) Estimate, Sales $104.000K Beat $70.714K Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658094581","title":"Cardiff Oncology Q2 Operating Expenses Fall on Lower R&D Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2658094581","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658094581?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:36","pubTimestamp":1786480574,"startTime":"0","endTime":"0","summary":"CORRECTED-Cardiff Oncology Q2 operating expenses fall on lower R&D costsCorrects to clarify second and third result drivers pertain to H1, not Q2OverviewUS biotech firm's Q2 operating expenses fell yr","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL1N448110:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","CRDF","ERAS","TOVX","BK4539","PRLD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658994341","title":"Cardiff Oncology Q2 Operating Expenses USD 9.719 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658994341","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658994341?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:27","pubTimestamp":1786480049,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nPLX9W08ZL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658943411","title":"Cardiff Oncology Q2 EPS USD -0.14","url":"https://stock-news.laohu8.com/highlight/detail?id=2658943411","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658943411?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:27","pubTimestamp":1786480049,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nPLX9W08ZL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658943188","title":"Cardiff Oncology Gugat Nerviano Atas Sengketa Lisensi Onvansertib","url":"https://stock-news.laohu8.com/highlight/detail?id=2658943188","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658943188?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:23","pubTimestamp":1786479807,"startTime":"0","endTime":"0","summary":"Cardiff Oncology gugat Nerviano atas sengketa lisensi onvansertibCardiff Oncology Inc. menggugat Nerviano Medical Sciences di Pengadilan Distrik AS Distrik Selatan California pada Mei 2026.Gugatan mem","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL5HNrPt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658948681","title":"Cardiff Oncology Rugi Bersih FY26 Kuartal II Menyempit Menjadi USD 21,6 Juta; Revenue Tetap USD 0,1 Juta","url":"https://stock-news.laohu8.com/highlight/detail?id=2658948681","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658948681?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:04","pubTimestamp":1786478668,"startTime":"0","endTime":"0","summary":"Cardiff Oncology rugi bersih FY26 kuartal II menyempit menjadi USD 21,6 juta; revenue tetap USD 0,1 jutaCardiff Oncology melaporkan revenue kuartal II berakhir 30 Juni 2026 tetap di USD 0,1 juta.Beban","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDLbF61k4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654032298","title":"Cardiff Oncology Inc Expected to Post a Loss of 16 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2654032298","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654032298?lang=en_us&edition=fundamental","pubTime":"2026-07-25 04:31","pubTimestamp":1784925065,"startTime":"0","endTime":"0","summary":"Cardiff Oncology Incexpected to post a loss of16cents a share - Earnings PreviewCardiff Oncology IncCRDF.OQCRDF.Ois expected to  show a fall in quarterly revenue when it reports  results on July 27 (e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nL8N43Q25H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652241394","title":"Cardiff Oncology CEO Mani Mohindru Acquires 34,364 Shares Worth $50,002.62","url":"https://stock-news.laohu8.com/highlight/detail?id=2652241394","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652241394?lang=en_us&edition=fundamental","pubTime":"2026-07-17 04:01","pubTimestamp":1784232101,"startTime":"0","endTime":"0","summary":"Cardiff Oncology CEO Mani Mohindru acquires 34,364 shares worth $50,002.62Cardiff Oncology CEO Mani Mohindru bought 34,364 common shares at $1.46, lifting direct holdings to 59,067 shares.He also acqu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260716:nNDLZWs50:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Cardiff Oncology CEO Mani Mohindru Acquires 34,364 Shares Worth $50,002.62","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651683384","title":"Cardiff Oncology Issues Warrants to Buy 9,303,136 Shares in Registered Direct Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2651683384","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651683384?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:02","pubTimestamp":1784116950,"startTime":"0","endTime":"0","summary":"Cardiff Oncology issues warrants to buy 9,303,136 shares in registered direct offeringCardiff Oncology launched a registered direct offering with warrants covering 9,303,136 common shares.Warrants pri","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nNDL3njctt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","BK4112","CRDF","BK4585","LU0314104364.USD","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4139","BK4588","IE00BN0W2W23.USD","SG9999014021.USD","NDAQ","IE00BN0W2V16.EUR","LU2210149790.SGD","LU2095319765.USD","IE00BKPKM429.USD","BCDF","SG9999014013.SGD","SG9999014005.SGD","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cardiffoncology.com","stockEarnings":[{"period":"1week","weight":0.068},{"period":"1month","weight":0.109},{"period":"3month","weight":-0.2568},{"period":"6month","weight":-0.4241},{"period":"1year","weight":-0.5067},{"period":"ytd","weight":-0.6085}],"compareEarnings":[{"period":"1week","weight":0.0055},{"period":"1month","weight":-0.0094},{"period":"3month","weight":0.0559},{"period":"6month","weight":0.15},{"period":"1year","weight":0.1805},{"period":"ytd","weight":0.1232}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.023989},{"month":2,"riseRate":0.5,"avgChangeRate":0.28397},{"month":3,"riseRate":0.357143,"avgChangeRate":0.075052},{"month":4,"riseRate":0.357143,"avgChangeRate":-0.062128},{"month":5,"riseRate":0.5,"avgChangeRate":0.055529},{"month":6,"riseRate":0.357143,"avgChangeRate":0.244554},{"month":7,"riseRate":0.4,"avgChangeRate":-0.096823},{"month":8,"riseRate":0.6,"avgChangeRate":0.104881},{"month":9,"riseRate":0.333333,"avgChangeRate":0.022271},{"month":10,"riseRate":0.5,"avgChangeRate":-0.014863},{"month":11,"riseRate":0.357143,"avgChangeRate":0.032453},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.01141}],"exchange":"NASDAQ","name":"Cardiff Oncology, Inc.","nameEN":"Cardiff Oncology, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cardiff Oncology, Inc.(CRDF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Cardiff Oncology, Inc.(CRDF) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Cardiff Oncology, Inc.,CRDF,Cardiff Oncology, Inc.股票,Cardiff Oncology, Inc.股票老虎,Cardiff Oncology, Inc.股票老虎国际,Cardiff Oncology, Inc.行情,Cardiff Oncology, Inc.股票行情,Cardiff Oncology, Inc.股价,Cardiff Oncology, Inc.股市,Cardiff Oncology, Inc.股票价格,Cardiff Oncology, Inc.股票交易,Cardiff Oncology, Inc.股票购买,Cardiff Oncology, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cardiff Oncology, Inc.(CRDF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Cardiff Oncology, Inc.(CRDF) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}